Republicans adding high-risk pool funding to save ACA replacement plan

House Republicans reportedly worked late into the night May 2 on further amendments to the American Health Care Act (AHCA) to address opposition from moderates about the bill’s lack of protections for people with pre-existing conditions.

According to the Independent Journal Review, the focus was on Reps. Fred Upton, R-Michigan, and Billy Long, R-Missouri. Upton had said on Holland, Michigan, radio station WHTC that he couldn’t support the bill as it “torpedoes” pre-existing conditions protections by allowing states to waive the ACA’s “community rating” provision, which opens the door to insurers charging customers higher premiums based on their medical history.

To earn their support, moderates and conservatives have agreed to add $8 billion in funding for high-risk pools to the legislation, which had already included $130 billion for that very purpose.

“I think we're finding that sweet spot,” a Republican aide told IJR.

Liberal groups, however, say the extra $8 billion is well short of what the high-risk pools would actually need. Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.